Jefferies puts Amgen on hold

Amgen, Inc. was rated at hold by Jefferies & Co., Inc. analyst Adam Walsh ahead of the company's third-quarter financial results. Walsh forecasts third-quarter total revenue of $3.5 billion and earnings per share of $0.99. IMS numbers indicate Aranesp and Enbrel may post stronger-than-expected third-quarter 2006 sales, according to the analyst. Shares of the Thousand Oaks, Calif.-based biotechnology company were up 90 cents, or 1.23%, at $73.95. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.